Department of Otolaryngology-Head & Neck Surgery, Johns Hopkins University School of Medicine, Baltimore, MD, United States.
Department of Oncology, Johns Hopkins University, Baltimore, MD, United States.
Oral Oncol. 2020 Jun;105:104652. doi: 10.1016/j.oraloncology.2020.104652. Epub 2020 Apr 2.
Human papillomavirus (HPV)-related oropharyngeal squamous cell cancer (OPSCC) has emerged as a distinct clinical entity of head and neck cancer with expected high survival. This recognition has led to the investigation of whether a population of patients can be identified who can safely undergo treatment de-escalation, in an effort to minimize long-term treatment toxicity while maintaining excellent survival. The purpose of this review is to describe the rationale for treatment deintensification for HPV-related OPSCC, summarize available results from published clinical trials, explore the methods by which risk groups are assigned, and provide context for the multitude of clinical trials that are currently underway.
人乳头瘤病毒（HPV）相关口咽鳞状细胞癌（OPSCC）已成为头颈部癌症的一个独特临床实体，预计具有较高的生存率。这种认识促使人们研究是否可以确定一类患者可以安全地进行治疗降级，以努力降低长期治疗毒性，同时保持良好的生存。本文综述的目的是描述 HPV 相关 OPSCC 治疗减量化的原理，总结已发表临床试验的结果，探讨风险组分配的方法，并为目前正在进行的大量临床试验提供背景。
